

bmchp.org | 888-566-0008



### **Pharmacy Policy**

# **Jelmyto**

**Policy Number:** 9.731 **Version Number:** 1.0

**Version Effective Date:** 9/1/2021

Product Applicability	☐ All Plan+ Products
Well Sense Health Plan  New Hampshire Medicaid	Boston Medical Center HealthNet Plan  ☐ MassHealth - MCO ☐ MassHealth - ACO ☐ Qualified Health Plans/ConnectorCare/Employer Choice Direct ☐ Senior Care Options

Note: Disclaimer and audit information is located at the end of this document.

## **Prior Authorization Policy**

#### **Products Affected:**

Jelmyto (mitomoycin)

The Plan may authorize coverage of the above products for members meeting the following criteria:

Covered	All FDA approved indications not otherwise excluded				
Use					
Exclusion	BCG treatment within the past 6 months				
Criteria	Perforation of the bladder or upper urinary tract				
Required	1. A diagnosis of low-grade upper tract urothelial cancer (LG-UTUC); AND				
Medical Information	2. At least one measurable papillary tumor that is 5 to 15 mm; <b>AND</b>				
	<ol><li>The member is not a candidate for, or is not seeking, nephrouresterectomy as a definitive treatment; AND</li></ol>				
	4. The member has had, or will have, complete or near complete endoscopic resection or ablation prior to gel application				

<sup>\*</sup> Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

Jelmyto

Age	18 years and older		
Restriction			
Prescriber	Prescribed by or in consultation with an oncologist		
Restriction			
Coverage	Initial: 6 weeks		
Duration	Reauthorization: 11 months		
Other criteria	<ol> <li>Reauthorization:</li> <li>Initial criteria are met; AND</li> <li>At least 3 months have elapsed since Jelmyto initiation and the member has had a complete response</li> </ol>		

## **Applicable Coding**

Code	Description
J9281	Mitomycin pyelocalyceal instillation, 1 mg

## **Clinical Background Information and References**

1. Jelmyto (mitomyin) [prescribing information]. UroGen Pharma, Inc. Princeton, NJ. January 2021.

Original Approval Date	Original Effective Date	Policy Owner	Approved by	
05/13/2021	9/1/2021	Pharmacy Services	Pharmacy & Therapeutics (P&T) Committee	

Policy Revisions History						
Review Date	Summary of Revisions	Revision Effective Date	Approved by			
5/13/2021	Policy created	9/1/2021	P&T Committee			

<sup>†</sup> Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

Jelmyto

#### **Next Review Date**

5/2022

### **Other Applicable Policies**

### Reference to Applicable Laws and Regulations, If Any

#### **Disclaimer Information**

Medical Policies are the Plan's guidelines for determining the medical necessity of certain services or supplies for purposes of determining coverage. These Policies may also describe when a service or supply is considered experimental or investigational, or cosmetic. In making coverage decisions, the Plan uses these guidelines and other Plan Policies, as well as the Member's benefit document, and when appropriate, coordinates with the Member's health care Providers to consider the individual Member's health care needs.

Plan Policies are developed in accordance with applicable state and federal laws and regulations, and accrediting organization standards (including NCQA). Medical Policies are also developed, as appropriate, with consideration of the medical necessity definitions in various Plan products, review of current literature, consultation with practicing Providers in the Plan's service area who are medical experts in the particular field, and adherence to FDA and other government agency policies. Applicable state or federal mandates, as well as the Member's benefit document, take precedence over these guidelines. Policies are reviewed and updated on an annual basis, or more frequently as needed. Treating providers are solely responsible for the medical advice and treatment of Members.

The use of this Policy is neither a guarantee of payment nor a final prediction of how a specific claim(s) will be adjudicated. Reimbursement is based on many factors, including member eligibility and benefits on the date of service; medical necessity; utilization management guidelines (when applicable); coordination of benefits; adherence with applicable Plan policies and procedures; clinical coding criteria; claim editing logic; and the applicable Plan – Provider agreement.

<sup>\*</sup> Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

Jelmyto